Highest development stage: Phase 3

Development status: Inactive

Gram-positive activity

Gram-negative activity

Propensity to select resistant bacteria

Mechanism of Action/Target pathogen: Inhibits protein synthesis by binding to 50S subunit; active against a number of Gram positives including MRSS and MRSA, this was more potent than vancomcyin and teicoplanin

Reason dropped: Pharmacokinetic complications

Additional information: Boucher HW, Thauvin-eliopoulos C, Loebenberg D, Eliopoulos GM. In vivo activity of evernimicin (SCH 27899) against methicillin-resistant Staphylococcus aureus in experimental infective endocarditis. Antimicrob Agents Chemother. 2001;45(1):208-11.